The NYT had an interesting piece discussing the National Institutes of Health collaboration with private companies in the development of new cancer drugs. As the piece points out, this collaboration has proven very profitable for the drug companies, but leads to drugs that are very expensive because the drug companies are allowed to have patent monopolies, with no restriction on the price they charge.
It also suggests an alternative path. It shows, contrary to conventional wisdom in right-win...
Published on December 19, 2016 21:35